Notes
2015 euros
Reference
Davis AE, et al. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clinical Trials 18: 214-222, No. 5, Nov 2017. Available from: URL: http://doi.org/10.1080/15284336.2017.1402144
Rights and permissions
About this article
Cite this article
Raltegravir cost efficient for treatment-naive HIV-1 in Spain. PharmacoEcon Outcomes News 794, 26 (2018). https://doi.org/10.1007/s40274-018-4624-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4624-9